TY - JOUR AB - Patients with non‑small cell lung cancer (NSCLC) are often positive for oncogenic driver mutations, such as EGFR, ALK, BRAF, RET and MET exon 14 skipping mutations (METex14 skipping). Recently, METex14 skipping has become a functional biomarker for NSCLC with the approval of MET kinase inhibitors. Tepotinib is an oral MET kinase inhibitor. Its overall response rate is 46%, and the median duration of the response is 11.1 months. In Japan, companion diagnostics for tepotinib are limited with the ArcherMET and AmoyDx test, but not with Oncomine Dx target test. The present study reports the case of a 60‑year‑old male patient with lung adenocarcinoma harboring METex14 skipping, which was positive on Oncomine DxTT, but not on ArcherMET. In his sample used for Oncomine DxTT, the read count of MET(13)‑MET(15) products was only 46. He was treated with various chemotherapeutic agents, but developed cardiac tamponade due to the progression of the disease of mediastinal lymph node metastases. Tepotinib was administered following pericardial drainage, resulting in an immediate response in all lesions. The majority of the discordant samples between Oncomine DxTT and ArcherMET had read counts <800, and the patient described herein had only 46. Therefore, the results of the present study indicate that the use of tepotinib should be considered even in patients whose METex14 skipping results were negative with ArcherMET, yet positive on Oncomine DxTT, particularly relatively with low lead counts. AD - Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa 236‑0051, Japan AU - Onodera,Yoko AU - Sekine,Akimasa AU - Hagiwara,Eri AU - Yamada,Sho AU - Ikeda,Satoshi AU - Tabata,Erina AU - Kitamura,Hideya AU - Baba,Tomohisa AU - Komatsu,Shigeru AU - Okudela,Koji AU - Ogura,Takashi DA - 2023/06/01 DO - 10.3892/mco.2023.2645 IS - 6 JO - Mol Clin Oncol KW - MET exon14 skipping Oncomine Dx target test Archer MET tepotinib lung cancer PY - 2023 SN - 2049-9450 2049-9469 SP - 49 ST - Successful tepotinib treatment of adenocarcinoma with MET exon 14 skipping and discordant results between Oncomine Dx target test and ArcherMET: A case report T2 - Molecular and Clinical Oncology TI - Successful tepotinib treatment of adenocarcinoma with MET exon 14 skipping and discordant results between Oncomine Dx target test and ArcherMET: A case report UR - https://doi.org/10.3892/mco.2023.2645 VL - 18 ER -